Press Releases

Press Releases

 
Press Releases
Date Title and Summary View
Oct 22, 2015 SAN DIEGO, Oct. 22, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing the ELAD® System, a cell-based therapy targeting the treatment of liver failure, today announced the pricing of an underwritten public offering of 5,454,546 newly issued shares of its common stock at a price to the public of $5....
Oct 22, 2015 SAN DIEGO, Oct. 22, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing the ELAD® System, a cell-based therapy targeting the treatment of liver failure, today announced that it intends to offer approximately $30,000,000 of shares of its common stock in an underwritten public offering. In addition, V...
Oct 16, 2015 SAN DIEGO, Oct. 16, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure, today provided an update on its clinical development program. The Company also announced an employee retention program and the date of its upcoming third quar...
Sep 28, 2015 SAN DIEGO, Sept. 28, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure, today outlined plans for a possible new phase 3 clinical trial designed to confirm ELAD's safety and efficacy in alcohol-induced liver decompensation (AILD),...
Sep 3, 2015 SAN DIEGO, Sept. 3, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure, today announced a workforce reduction of approximately 30% and plans to institute across the board expense reductions to conserve capital. The Company expects...
Aug 31, 2015 SAN DIEGO, Aug. 31, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure, today announced that additional data from its VTI-208 clinical trial were presented by two principal investigators of the study at the 16th International Symp...
Aug 21, 2015 SAN DIEGO, Aug. 21, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure, today announced that topline results from VTI-208, the Company's phase 3 randomized, controlled, open-label trial, evaluating the ELAD System in subjects with...
Jul 30, 2015 SAN DIEGO, July 30, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure, today announced results for the second quarter ended June 30, 2015 and provided a corporate update. "As we approach data lock and analysis of VTI-208 ...
Jul 27, 2015 SAN DIEGO, July 27, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure, will release its second quarter 2015 financial results after the market closes on Thursday, July 30, 2015. The press release will be followed by a conference ...
Jul 15, 2015 SAN DIEGO, July 15, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure, today announced that Cheryl Cohen, the former Chief Commercial Officer of Medivation, Inc., has been appointed to its Board of Directors, effective immediatel...
Page: FirstPrevious
3
... NextLast
= add release to Briefcase